Engineered immune cells take on multiple sclerosis and other nerve disorders

NCT ID NCT07304154

First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 27 times

Summary

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune nerve diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that have not responded to standard therapies. KITE-363 uses a patient's own immune cells, modified to target and attack faulty immune cells causing the disease. The study aims to check safety, find the right dose, and see if it can control these conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Concord Repatriation General Hospital

    RECRUITING

    Sydney, New South Wales, 2139, Australia

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • LDS Hospital - Intermountain Health

    RECRUITING

    Salt Lake City, Utah, 84143, United States

  • Stanford Neuroscience Health Center

    RECRUITING

    Palo Alto, California, 94304, United States

Conditions

Explore the condition pages connected to this study.